Increased neutrophil lymphocyte ratio and platelet lymphocyte ratio in malignant parotid tumors.

INTRODUCTION: Recently it has been reported that a high preoperative neutrophil-lymphocyte ratio and platelet-lymphocyte ratio may be related to increased recurrence risk, tumor aggressiveness, and worsened prognosis in various malignancies. OBJECTIVE: The objective of this research is to explore whether neutrophil-lymphocyte ratio and platelet-lymphocyte ratio in parotid tumors may or may not be used as a cancer marker. METHODS: This retrospective research has been conducted on a total of 228 patients consisting of 83 healthy persons and 145 patients with a mass in the parotid gland, who applied to a tertiary referral center and underwent surgery. Patients have been divided into two groups by their histopathological findings as malignant or benign parotid tumor. A third group consisting of healthy people has been defined as the control group. Also the malignant parotid tumor group has been divided into two subgroups as early stage and advanced stage. The groups have been compared in terms of neutrophil-lymphocyte ratio, platelet-lymphocyte ratio and other laboratory data. RESULTS: The average neutrophil-lymphocyte ratio values of malignant parotid tumor, benign parotid tumor, healthy control groups were 2.51, 2.01, 1.79 respectively and the difference was statistically significant (p<0.001). There was no significant difference between advanced stage and early stage parotid tumor groups in terms of average neutrophil-lymphocyte ratio value (p=0.782). In dual comparisons, the platelet-lymphocyte ratio value of patients in the malignant group was found out to be statistically significantly higher than that of benign and control groups (p<0.001 and p=0.001 respectively). CONCLUSION: To the best of our knowledge our research is the first in the medical literature comparing neutrophil-lymphocyte ratio and platelet-lymphocyte ratio in patients with parotid tumor. neutrophil-lymphocyte ratio and platelet-lymphocyte ratio can serve as cost-effective, repeatable, easily accessible, and helpful inflammatory markers in order to distinguish patients with malignant parotid tumor from healthy people.

Novel interleukin-33 and its soluble ST2 receptor as potential serum biomarkers in parotid gland tumors.

An increasing number of patients with parotid gland tumors have been observed in recent years. The relationship between the immune system and tumor formation is thoroughly investigated. However, newly discovered molecules offer a new insight into the pathophysiology of malignancies. It would be ideal to find an easily determinable biomarker of tumor existence, its malignant potential or a biomarker suggesting the probability of disease recurrence. Our study is the first to examine serum concentrations of IL-33 and its sST2 receptor in patients with various types of parotid gland tumors. Serum IL33, sST2, IL-4 and IL-10 concentrations were determined in patients with benign and malignant parotid gland tumors (pleomorphic adenoma, Warthin's tumor, myoepithelioma and acinic cell carcinoma). We observed for the first time that serum IL-33 level was significantly elevated in patients with various types of parotid gland tumors and sST2 levels were significantly higher in pleomorphic adenoma and acinic cell carcinoma patients compared to the controls. Our results demonstrate for the first time that serum IL-33 and its sST2 receptor may be important factors in the pathology of parotid gland tumors. Although our results are promising, further investigations are required to detect if serum concentrations of those molecules may be a biomarker in parotid gland tumors. Impact statement Parotid gland tumors seem to be an increasingly important medical challenge, mostly due to a noticeable increase in the incidence. It would be crucial to find an easily determinable biomarker of tumor existence, its recurrence or malignant potential. We observed for the first time that serum IL-33 level was significantly elevated in patients with various types of parotid gland tumors and its sST2 receptor levels were significantly higher in pleomorphic adenoma and acinic cell carcinoma patients compared to the controls. We believe that our study helps to understand the biology of the tumors and a potential role of a relatively newly identified cytokine IL-33 in the pathophysiology of the parotid gland tumors.

Investigation of IL-33 serum levels in patients with benign and malignant salivary gland tumors.

BACKGROUND: Interleukin-33 (IL-33) has been recently discovered as an influential factor in the process of tumor immunity, and is presented in cancer pathogenesis. OBJECTIVE: This study aimed to determine the serum levels of IL-33 in patients with benign and malignant Salivary gland tumors (SGTs). METHODS: This descriptive cross-sectional study was performed on 47 samples of malignant SGTs including 18 mucoepidermoid carcinoma (MEC), 8 adenoid cystic carcinoma (ADCC), 21 malignant mixed tumor (MMT), and 14 benign pleomorphic adenoma (PA). A control group was considered consisting of 28 healthy subjects. The serum level of IL-33 was measured by using sandwich ELISA method. The data were statistically analyzed through Kruskal-Wallis and Mann-Whitney tests. RESULTS: The median concentration of IL-33 was 6.91 in malignant, 5.14 in benign, and 5.01 in healthy cases, with a statistically significant difference (P= 0.001). The median serum levels of IL-33 increased significantly in ADCC (7.15), MEC (7.03), and MMT (6.91) compared with the control group (5.01) (P< 0.05). The mean rank of MEC was significantly higher than PA (P= 0.01). IL-33 concentration was positively and significantly correlated with the tumor stage (P= 0.02) and tumor size (P= 0.03). CONCLUSIONS: IL-33 could be suggested as a novel biomarker to distinguish different types of SGTs.

Granulocyte colony stimulating factor-producing lung cancer with severe anemia of inflammation.

Granulocyte colony stimulating factor (G-CSF)-producing lung cancer occasionally induces severe inflammation with an abnormally high white blood cell count. Herein, we report a 49-year-old man who suffered from resectable G-CSF-producing non-small cell lung cancer with continuous fever and severe anemia. Red blood cell transfusion was necessary for the anemia of inflammation. The patient underwent complete surgical tumor resection. The histopathological diagnosis was a pleomorphic carcinoma at pathological stage IIB. This is apparently the first successful case of surgical resection of G-CSF-producing lung cancer in a patient with severe anemia and uncontrollable fever.

Increased neutrophil lymphocyte ratio and platelet lymphocyte ratio in malignant parotid tumors / Relação neutrófilo-linfócito aumentada e relação plaqueta-linfócito em tumores malignos da parótida

Abstract Introduction Recently it has been reported that a high preoperative neutrophil-lymphocyte ratio and platelet-lymphocyte ratio may be related to increased recurrence risk, tumor aggressiveness, and worsened prognosis in various malignancies. Objective The objective of this research is to explore whether neutrophil-lymphocyte ratio and platelet-lymphocyte ratio in parotid tumors may or may not be used as a cancer marker. Methods This retrospective research has been conducted on a total of 228 patients consisting of 83 healthy persons and 145 patients with a mass in the parotid gland, who applied to a tertiary referral center and underwent surgery. Patients have been divided into two groups by their histopathological findings as malignant or benign parotid tumor. A third group consisting of healthy people has been defined as the control group. Also the malignant parotid tumor group has been divided into two subgroups as early stage and advanced stage. The groups have been compared in terms of neutrophil-lymphocyte ratio, platelet-lymphocyte ratio and other laboratory data. Results The average neutrophil-lymphocyte ratio values of malignant parotid tumor, benign parotid tumor, healthy control groups were 2.51, 2.01, 1.79 respectively and the difference was statistically significant (p < 0.001). There was no significant difference between advanced stage and early stage parotid tumor groups in terms of average neutrophil-lymphocyte ratio value (p = 0.782). In dual comparisons, the platelet-lymphocyte ratio value of patients in the malignant group was found out to be statistically significantly higher than that of benign and control groups (p < 0.001 and p = 0.001 respectively). Conclusion To the best of our knowledge our research is the first in the medical literature comparing neutrophil-lymphocyte ratio and platelet-lymphocyte ratio in patients with parotid tumor. neutrophil-lymphocyte ratio and platelet-lymphocyte ratio can serve as cost-effective, repeatable, easily accessible, and helpful inflammatory markers in order to distinguish patients with malignant parotid tumor from healthy people.

Resumo Introdução Recentemente, tem sido relatado que as relações neutrófilo-linfócito e plaqueta-linfócito aumentadas no pré-operatório podem estar relacionadas ao aumento do risco de recorrência e agressividade do tumor e pior prognóstico em várias neoplasias malignas. Objetivo Investigar se as relações neutrófilo-linfócito e plaqueta-linfócito em tumores da parótida podem ou não serem utilizadas como marcadores de câncer. Método Esta pesquisa retrospectiva foi conduzida com 228 indivíduos, 83 saudáveis e 145 com tumor de parótida, os quais foram encaminhados a um centro de referência terciária e operados. Os pacientes foram divididos em dois grupos de acordo com os achados histopatológicos de malignidade e benignidade. O terceiro grupo foi composto por indivíduos saudáveis, foi definido como o grupo controle. Além disso, o grupo com tumores malignos da parótida foi dividido em dois subgrupos, um com pacientes em estágio inicial da doença e o outro com pacientes em estágio avançado. Os grupos foram comparados em termos das relações neutrófilo-linfócito e plaqueta-linfócito e outros dados laboratoriais. Resultados Os valores médios da relação neutrófilo-linfócito do tumor maligno de parótida, do tumor benigno de parótida e do grupo controle foram de 2,51, 2,01 e 1,79, respectivamente, com uma diferença estatisticamente significante (p < 0,001). Não houve diferença estatística entre os grupos em estágio avançado e em estágio inicial em termos de valor médio da relação neutrófilo-linfócito (p = 0,782). Em comparações duplas, o valor da relação plaqueta-linfócito dos pacientes do grupo do grupo com tumor maligno foi estatisticamente maior do que nos grupos com tumor benigno e controle (p < 0,001 e p = 0,001, respectivamente). Conclusão Que seja de nosso conhecimento, nosso estudo é o primeiro na literatura médica a comparar a relação neutrófilo-linfócito e a relação plaqueta-linfócito em pacientes com tumor de parótida. As relações neutrófilo-linfócito e plaqueta-linfócito podem servir como marcadores inflamatórios de baixo custo, reproduzíveis, de fácil acesso e úteis, a fim de distinguir os pacientes com tumor maligno de parótida de pessoas saudáveis.

[Serum selenium in patients with epidermoid carcinoma of the oral cavity and pleomorphic adenoma of the salivary glands]. / Koncentracija selena u serumu obolelih osoba od planocelulnog karcinoma u usnoj supljini i pleomorfnog adenoma pljuvacnih zlezda.

In 23 patients with epidermoid carcinoma of the oral cavity and in 13 patients with pleomorphic adenoma of the salivary gland blood selenium level was studied with hydride atomic absorptive spectrophotometry. Serum selenium was significantly lower in patients with epidermoid carcinoma of the oral cavity (79.37% lower than control values). In patients with pleomorphic adenoma of the salivary gland values were lower by 32.20% than control values. The results suggest the need of further epidemiological studies in order to determine the selenium concentration in the ground and the food. In this way the optimal dose of selenium for prevention of benignant and malignant diseases in the maxillofacial region, can be established.

The occurrence of blood group substances (A, B, H, Le-a, Le-b) in salivary glands and salivary gland tumors. An immunohistochemical investigation.

The distribution of blood group substances A, B, H, Le-a and Le-b in normal and neoplastic salivary gland tissue was evaluated by means of immunohistochemistry. The serological ABH blood group status of one third of the patients was known. Lewis blood group and secretory status were not known. In normal tissue, expression of blood group antigens corresponded to the serological blood group. Blood group substance H was present in almost every gland, regardless of the serological blood group. In submandibular glands, Le-b was rather selective for mucous acini. In tumors, a relationship of blood group expression to a glandular pattern and a high differentiation could be observed. Blood group substances were expressed at a high level in benign and highly differentiated malignant tumors. In poorly differentiated malignant tumors, they were mostly absent. Blood group expression evaluation could be of value in establishing the level of functional differentiation in salivary gland tumors.

ABO blood groups and salivary gland tumors (Alabama, United States).

Studies of associations between various diseases and the ABO blood groups have shown elevated relative risks for some categories of disease. A strong association between salivary gland tumors and blood group A has been reported, but studies are few and have yielded contradictory results. To investigate this association, we conducted an epidemiologic study of salivary gland tumors diagnosed in Jefferson Country, Alabama (United States), 1968-89. All tumors were histologically confirmed. Blood group information was obtained for 200 individuals with salivary gland tumors, and the distribution of ABO and Rh blood type for cases was compared with that of 52,118 healthy blood donors from the same geographic area. The 38.5 percent of salivary gland tumors in cases with blood group A was similar to the 39.0 percent observed for controls (P = 0.95). No differences were observed when benign and malignant tumors were considered separately, nor for any of the major histologic types of tumor. The distribution of Rh factor among cases and controls also did not differ significantly (P = 0.08).